Compare RAVE & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | BTAI |
|---|---|---|
| Founded | 1958 | 2017 |
| Country | United States | United States |
| Employees | N/A | 37 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 38.5M |
| IPO Year | 1995 | 2018 |
| Metric | RAVE | BTAI |
|---|---|---|
| Price | $2.97 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 25.6K | ★ 310.9K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $15,120,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $261.81 |
| P/E Ratio | $33.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.01 | $1.17 |
| 52 Week High | $3.75 | $8.08 |
| Indicator | RAVE | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | 48.75 |
| Support Level | $2.73 | $1.50 |
| Resistance Level | $3.21 | $1.72 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 11.27 | 53.12 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.